- Home
- CNTA vs DNLI Comparison
CNTA vs DNLI Comparison
Compare CNTA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | DNLI |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNTA | DNLI |
|---|---|---|
| Price | $39.85 | $19.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $42.50 | $34.09 |
| AVG Volume (30 Days) | ★ 3.2M | 1.7M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $188.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $10.57 |
| 52 Week High | $40.26 | $23.77 |
Technical Indicators
Market Signals| Indicator | CNTA | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 78.06 | 47.30 |
| Support Level | $22.49 | $18.56 |
| Resistance Level | N/A | $20.12 |
| Average True Range (ATR) | 1.66 | 1.14 |
| MACD | 1.11 | -0.21 |
| Stochastic Oscillator | 97.05 | 30.89 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.